Turner lab has established a patient-derived xenograft (PDX) model of ALK-positive anaplastic large cell lymphoma (ALCL), which gave me access to fresh tumor samples.

My doctoral research focuses on drug-tolerant persister cells (DTPs) and drug resistance mechanisms in ALK+ anaplastic large cell lymphoma (ALCL) and other ALK+ malignancies, such as non-small cell lung cancer (NSCLC).

As part of the FANTOM EU project, I spent two weeks at CBmed in Graz, working on image analysis within the field of spatial proteomics, which was recently named Method of the Year 2024.